White paper from Shift.MS outlines COVID’s ongoing impact on MS community

9 December, 2020 | Posted in:

MS online community Shift.MS have published a white paper detailing the ongoing impact of COVID-19 on the MS community as reported by people living with MS themselves.  Sending out an online survey in September this year, Shift.MS received almost 1,500 responses and have used this to inform the white paper, as well as to develop a short awareness video, and […]

Continue Reading »

MS Advanced MasterClass project winner announced!

20 November, 2020 | Posted in:

This week our MS Advanced MasterClass took place and nine delegates gave virtual presentations of their projects.  The winning project was presented by Chandni Radia, a lead neuroscience pharmacist based at Imperial College Healthcare NHS Trust. Her work focussed on prevention of risk in ocrelizumab through early B-cell monitoring.  Her review of 170 people with […]

Continue Reading »

ADIOS – adaptive ocrelizumab dosing study

21 September, 2020 | Posted in:

Dear MS Academy Member, We are exploring a funding application to perform an Adaptive Ocrelizumab Dosing Study or ADIOS trial. The idea is to try and adjust the dosing regimen of ocrelizumab to derisk some of the emerging adverse events associated with long-term B cell depletion. Would you be interested in participating? If yes, do you mind completing the […]

Continue Reading »

International Virtual MasterClass – the first of its kind!

17 September, 2020 | Posted in:

Our first ever International Virtual MasterClass ran last month over a period of two weeks, attended by 53 healthcare professionals from around the globe.  Co-created by Roche Egypt, the MasterClass was specifically focussed on multiple sclerosis (MS), and provided a virtual learning experience for delegates across 10 countries (table 1) where specialists in the condition […]

Continue Reading »

Essential neurorehabilitation in the aftermath of COVID-19

6 July, 2020 | Posted in: ,

The impact of coronavirus on our health service has been highly documented, but with the first wave passed, the burden has not lifted, but altered, in the form of rehabilitation. Earlier this week, we highlighted an article in Reuters which has since been echoed in multiple publications – the long-term implications of COVID-19 on a […]

Continue Reading »

World MS Day 2020

30 May, 2020 | Posted in:

World MS is officially marked on 30th May. It brings the global MS community together to share stories, raise awareness and campaign with everyone affected by multiple sclerosis (MS). World MS Day activities take place throughout the month of May and in early June. The campaign offers flexibility for individuals and organisations to achieve a […]

Continue Reading »

Fampyra approved in Scotland

17 April, 2020 | Posted in:

The Scottish Medicines Consortium (SMC) have approved ‘Fampyra’ for use by people living with multiple sclerosis (MS) in Scotland. Around 2 in 3 people with MS will develop walking difficulties and the drug, fampridine, improves walking ability in those responsive to it; around 1 in 3 people who try it (Biogen). Developed by Biogen Idec, […]

Continue Reading »